Navigation Links
Cardica Announces Publication of Case Report in the Journal of Neurosurgery Featuring Use of C-Port(R) System in Brain Arterial Bypass
Date:11/10/2008

- Dr. Ralph G. Dacey, Jr., Successfully Uses C-Port System to Bypass

Cerebral Aneurysm in Patient with Brain Injury -

REDWOOD CITY, Calif., Nov. 10 /PRNewswire-FirstCall/ -- Cardica, Inc. (Nasdaq: CRDC) today announced publication of a case study in the September issue of the peer-reviewed Journal of Neurosurgery featuring the use of Cardica's C-Port xA(R) Distal Anastomosis System to connect blood vessels in the brain to bypass an enlarging aneurysm.

Ralph G. Dacey, Jr., M.D., professor and chairman of neurological surgery at Washington University School of Medicine in St. Louis, and his colleagues performed neurosurgery on a 43-year-old male patient who sustained a subarachnoid hemorrhage after being assaulted and, as a result, experienced an enlarging aneurysm. Using the C-Port system, the neurosurgeons bypassed the aneurysm using a saphenous vein graft extending from the extracranial common carotid artery to the intracranial middle cerebral artery. The C-Port system performed an automated anastomosis by inserting 13 tiny staples into the graft and recipient vessel. The bypass was demonstrated to be patent (open) on intraoperative and postoperative arteriography, and the patient subsequently made a good neurologic recovery.

"By using the C-Port system instead of hand sewing the vessels in the brain, we were able to reliably connect the graft vessel and significantly reduce the length of time that blood flow was cut off from the brain in this patient," said Dr. Dacey. "In appropriate patients, we believe the C-Port system is a useful addition to the arsenal of tools that neurovascular surgeons have to surgically bypass cerebral aneurysms. We are looking forward to using it in other suitable cases." <
'/>"/>

SOURCE Cardica, Inc.
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3

Related medicine news :

1. Cardica to Present at William Blair Small-Cap Growth Stock Conference
2. Cardica to Host Conference Call at 11:00 a.m. Eastern Time Tomorrow to Provide Positive Update on Pas-Port(R)
3. Cardica to Announce Fiscal 2008 Fourth Quarter and Year End Financial Results on Tuesday, August 5, 2008
4. Cardica Names Frederick Bauer Vice President of Operations
5. Renowned Leader and Educator in Robotic Cardiac Bypass Surgery Leverages Cardicas C-Port(R) Flex-A(R) Anastomosis System in His Practice and to Educate Cardiothoracic Surgeons
6. Cardica, Intuitive Surgical, MAQUET Cardiovascular and Transonic to Host Innovations in Revascularization Symposium
7. Cardica to Announce Fiscal 2008 Third Quarter Financial Results on Tuesday, April 29, 2008
8. Cardicas C-Port Anastomosis Systems Facilitate Beating Heart Bypass Surgery in Study
9. Cardicas C-Port Anastomosis Systems for Coronary Artery Bypass Graft Procedures to be Used to Train Cardiothoracic Surgeons at Society of Thoracic Surgeons (STS) University
10. Cardica to Announce Fiscal 2008 Second Quarter Financial Results on Thursday, January 24, 2008
11. Cardica Announces Exercise of Over-Allotment Option
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2009)...rt Principles to Govern Health Insurer Behavior ,...wire/ -- Nearly nine out of ten voters (88%) belie...nfluence over how doctors care for their patients ...ept of a "Health Insurer Code of Conduct" that wou...th insurance companies with respect to how they de...
(Date:7/2/2009)...SNewswire/ -- Acetaminophen is an ingredient found...es to help relieve pain and reduce fever. Many pe...ol and prescription brand names, Vicodin and Perco... on June 30, 2009 to address liver related injurie...voted 20-17 to urge the FDA to put a ban on Vicodi...
(Date:7/2/2009)...e/ -- Dr Daniel Goldberg, a leading New Jersey oph...e the effectiveness of using 5% Betadine irrigatio...e, highly contagious and often severe form of conj... impairment due to corneal involvement. , , Oph...ster to participate in the Betadine for EKC study....
(Date:7/2/2009)...swire/ -- A new analysis of the incidence of breas...es of 0 to 84 from 2000 to 2005 shows a 72 percent...stry of Health, with the sharpest uptick of +28.6 ...25 to 44). , , The new results, which rely on h...urgeries rather than official estimations computed...
Breaking Medicine News(10 mins):Health News:4 out of 5 CA Voters Demand Health Insurer "Code of Conduct" 2Health News:4 out of 5 CA Voters Demand Health Insurer "Code of Conduct" 3Health News:4 out of 5 CA Voters Demand Health Insurer "Code of Conduct" 4Health News:4 out of 5 CA Voters Demand Health Insurer "Code of Conduct" 5Health News:4 out of 5 CA Voters Demand Health Insurer "Code of Conduct" 6Health News:Viles & Beckman, LLC: Stop Your Headache NOT Your Liver 2Health News:Ophthalmologists Invited To Participate in Betadine for EKC Treatment Study 2Health News:Rate of Breast Cancer in Italy Significantly Higher Than Previously Reported 2Health News:Rate of Breast Cancer in Italy Significantly Higher Than Previously Reported 3
...Sweden warn women undergoing hormone replacement ...ne Replacement Therapy is advised for women to red...ight sweats, and to protect them from osteoporosis...h has shown the drugs, which replace natural hormo...
...stitute of Marine Science (AIMS) and an Australian...ave reached agreement to develop the coral sunscre...future. Corals have developed natural sunscreens t...high-intensity ultraviolet radiation penetrating s...
...e retinal vein could not only make you loose your ...ked veins is so painful that the eye may have to b...California have devised a new instrument that uses...s of blockage-dissolving drugs into a clogged vein...
... is one disease that can have Complication as its ...abetic could have, the dreaded would be the foot u...putation. For diabetics with this dreaded foot ulc...vice that delivers a high voltage electric current...
Other Medicine News:Health News:Blocked viens block eye sight 2
(Date:6/29/2009)...Biotherapeutics Based On Naturally Resected tRNA S... -- Pangu BioPharma, a subsidiary of aTyr Pharma i...rd patent application on proprietary, naturally oc...h tRNA synthetases are universal and essential com...l organisms, human synthetases have naturally occu...
(Date:6/28/2009)...tugal, June 29 Data presented,tod...t with the novel,once-daily anti-epileptic Zebin... a marked and sustained decrease in seizure freque...he one-year extension of a pivotal Eslicarbazepine...ternational Congress for Epilepsy in,Budapest, Hu...
(Date:6/26/2009)...Newswire-FirstCall/ -- Sanofi-aventis (EURONEXT:... data associated with a retrospective follow-up of...a clearly show that no definitive conclusions can ...between Lantus(R) (insulin glargine [rDNA] injecti... authors of the study point out. , , Clinical s...
(Date:6/26/2009)...proval of New Anti-TNF Therapy in Three Rheumatic ... , HORSHAM, Pa. and KENILWORTH, N.J., June 26 /PR... and Schering-Plough Corporation (NYSE: SGP ) an...ducts for Human Use (CHMP) of the European Medicin...ending the approval of SIMPONI(TM) (golimumab) as ...
Breaking Medicine Technology:Pangu BioPharma, aTyr Pharma's Subsidiary in Hong Kong, Files Three Patent Applications 2Pangu BioPharma, aTyr Pharma's Subsidiary in Hong Kong, Files Three Patent Applications 3Data Demonstrates Long-Term Reduction In Seizure Frequency With Novel Once Daily Anti-Epileptic Zebinix(R) 2Data Demonstrates Long-Term Reduction In Seizure Frequency With Novel Once Daily Anti-Epileptic Zebinix(R) 3Data Demonstrates Long-Term Reduction In Seizure Frequency With Novel Once Daily Anti-Epileptic Zebinix(R) 4Data Demonstrates Long-Term Reduction In Seizure Frequency With Novel Once Daily Anti-Epileptic Zebinix(R) 5Data Demonstrates Long-Term Reduction In Seizure Frequency With Novel Once Daily Anti-Epileptic Zebinix(R) 6Data Demonstrates Long-Term Reduction In Seizure Frequency With Novel Once Daily Anti-Epileptic Zebinix(R) 7Sanofi-aventis Stands Behind the Safety of Lantus(R) 2Sanofi-aventis Stands Behind the Safety of Lantus(R) 3SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 2SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 3SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 4SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 5SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 6SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 7SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 8SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 9SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 10New Study 3A Antidepressants Commonly Prescribed with Tamoxifen Put Women at Much Higher Risk for Recurrent Breast Cancer 4484 1New Study 3A Antidepressants Commonly Prescribed with Tamoxifen Put Women at Much Higher Risk for Recurrent Breast Cancer 4484 2New Study 3A Antidepressants Commonly Prescribed with Tamoxifen Put Women at Much Higher Risk for Recurrent Breast Cancer 4484 3New Study 3A Antidepressants Commonly Prescribed with Tamoxifen Put Women at Much Higher Risk for Recurrent Breast Cancer 4484 4New Study 3A Antidepressants Commonly Prescribed with Tamoxifen Put Women at Much Higher Risk for Recurrent Breast Cancer 4484 5OncoGenex Pharmaceuticals Announces OGX 427 Treatment Demonstrates Safety Evidence of Declines in Circulating Tumor Cells and Reductions in Tumor Mar 12365 1OncoGenex Pharmaceuticals Announces OGX 427 Treatment Demonstrates Safety Evidence of Declines in Circulating Tumor Cells and Reductions in Tumor Mar 12365 2OncoGenex Pharmaceuticals Announces OGX 427 Treatment Demonstrates Safety Evidence of Declines in Circulating Tumor Cells and Reductions in Tumor Mar 12365 3OncoGenex Pharmaceuticals Announces OGX 427 Treatment Demonstrates Safety Evidence of Declines in Circulating Tumor Cells and Reductions in Tumor Mar 12365 4OncoGenex Pharmaceuticals Announces OGX 427 Treatment Demonstrates Safety Evidence of Declines in Circulating Tumor Cells and Reductions in Tumor Mar 12365 5Video 3A Phase III Study Data With Vandetanib 28Zactima 28TM 29 29 in Patients With Advanced Non Small Cell Lung Cancer 28NSCLC 29 Presented at Amer 4482 1Video 3A Phase III Study Data With Vandetanib 28Zactima 28TM 29 29 in Patients With Advanced Non Small Cell Lung Cancer 28NSCLC 29 Presented at Amer 4482 2Video 3A Phase III Study Data With Vandetanib 28Zactima 28TM 29 29 in Patients With Advanced Non Small Cell Lung Cancer 28NSCLC 29 Presented at Amer 4482 3Video 3A Phase III Study Data With Vandetanib 28Zactima 28TM 29 29 in Patients With Advanced Non Small Cell Lung Cancer 28NSCLC 29 Presented at Amer 4482 4Video 3A Phase III Study Data With Vandetanib 28Zactima 28TM 29 29 in Patients With Advanced Non Small Cell Lung Cancer 28NSCLC 29 Presented at Amer 4482 5Wyeth Donates 24100 000 to ASCO Cancer Foundation 28R 29 to Support Cancer Prevention and Care 47367 1Wyeth Donates 24100 000 to ASCO Cancer Foundation 28R 29 to Support Cancer Prevention and Care 47367 2Wyeth Donates 24100 000 to ASCO Cancer Foundation 28R 29 to Support Cancer Prevention and Care 47367 3
...NGTON, March 15, 2007 /PRNewswire/ -- Up to two mi...h up to 600,000,hospitalized. Its primary complica...0 lives annually -- more than breast cancer and,AI...Thrombosis (DVT) recently,sponsored an online surv...ers and physicians. The survey, which was conducte...
...ng-Plough Announces Presentation Of Phase II Trial...st At The 2007 Annual,Meeting Of The American Coll...ch 16, 2007 /PRNewswire-FirstCall/ --,Schering-Plo...e,Phase II trial of its novel oral thrombin recept...t the 2007 annual Scientific Sessions,of the of Ca...
Other Medicine Technology:DVT Awareness Survey Findings for Respondents in High-Risk Groups:,Obese Individuals 2Media Advisory: ACC Updated Schedule 2
...boratories is a national reference laboratory and ...ch and development. ARUP offers an extensive test ... clinical and anatomic pathology. Owned by the Uni...e more than half of the nation's university teachi...
...boratories is a national reference laboratory and ...ch and development. ARUP offers an extensive test ... clinical and anatomic pathology. Owned by the Uni...e more than half of the nation's university teachi...
...boratories is a national reference laboratory and ...ch and development. ARUP offers an extensive test ... clinical and anatomic pathology. Owned by the Uni...e more than half of the nation's university teachi...
...boratories is a national reference laboratory and ...ch and development. ARUP offers an extensive test ... clinical and anatomic pathology. Owned by the Uni...e more than half of the nation's university teachi...
Medicine Products: